Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results
12 août 2024 06h30 HE
|
Apogee Therapeutics, LLC
Continued advancement of pipeline and execution towards expected milestones, including APG777 16-week proof-of-concept data from the Phase 2 Part A trial in 2H 2025, APG808 interim Phase 1 data in 4Q...
Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD
28 mai 2024 07h30 HE
|
Apogee Therapeutics, LLC
SAN FRANCISCO and WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the...
Apogee Therapeutics to Participate in Upcoming June Investor Conferences
23 mai 2024 07h30 HE
|
Apogee Therapeutics, LLC
SAN FRANCISCO and WALTHAM, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the...
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
15 mai 2024 16h01 HE
|
Apogee Therapeutics, LLC
Interim clinical data from APG777 Phase 1 healthy volunteers study exceeded all trial objectives and achieved a half-life of approximately 75 days with a potentially best-in-class profile 16-week...
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results
13 mai 2024 07h00 HE
|
Apogee Therapeutics, LLC
Initiated a Phase 2 clinical trial of APG777, a subcutaneous half-life extended monoclonal antibody targeting IL-13, in patients with moderate-to-severe atopic dermatitis, with 16-week...
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
25 mars 2024 07h00 HE
|
Apogee Therapeutics, LLC
Preclinical data with APG808 demonstrate the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks compared to dosing...
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million
12 mars 2024 16h01 HE
|
Apogee Therapeutics, LLC
SAN FRANCISCO, Calif. and WALTHAM, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated...
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
07 mars 2024 18h49 HE
|
Apogee Therapeutics, LLC
SAN FRANCISCO and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for...
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
05 mars 2024 16h23 HE
|
Apogee Therapeutics, LLC
SAN FRANCISCO and WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for...
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
05 mars 2024 06h10 HE
|
Apogee Therapeutics, LLC
Positive interim results from APG777 Phase 1 healthy volunteer clinical trial exceeded objectives with approximately 75-day half-life which supports the potential for higher exposures leading to...